NCT04662788

Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies

Clinical Trial for the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 15 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Clinical study on the safety and effectiveness of NK cells/combined monoclonal antibodies in the treatment of hematological malignancies

Detailed description

This is a single arm, open-label, single-center study. This study is indicated for hematological malignancies. The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 36 patients will be enrolled. Primary objective is to explore the safety, main consideration is dose-related safety.

Conditions

• Hematological Malignancies

Interventions

Type	Name	Description
DRUG	NK cells/Combined Monoclonal Antibodies	Each subject receive NK cells/Combined Monoclonal Antibodies

Timeline

• Start date: 2021-01-01
• Primary completion: 2024-01-01
• Completion: 2027-01-01
• First posted: 2020-12-10
• Last updated: 2020-12-10

Locations

1 site across 1 country: China